Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.35 |
| ▸ | PPARA | Q07869 | 8/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27628219 | 0.86 | CYP4F2 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL6258518 | 0.83 | CYP4F2 (0.39) | CYP4F2CYP4A11PPARATTRCYP1A2 | |
| SCHEMBL5529576 | 0.83 | ACLY (0.46) | CYP4F2CYP4A11PPARATTRCYP1A2 | |
| SCHEMBL22016456 | 0.80 | ACLY (0.46) | CYP4F2CYP4A11PPARATTRCYP1A2 | |
| SCHEMBL2981249 | 0.79 | CYP4F2 (0.44) | CYP4F2CYP4A11CYP1A2TSHRACLY | |
| SCHEMBL20375533 | 0.79 | CYP4F2 (0.43) | CYP4F2CYP4A11PPARATSHRTDP1 | |
| SCHEMBL27438732 | 0.79 | ACLY (0.49) | CYP4F2CYP4A11PPARATTRCYP1A2 | |
| SCHEMBL8057594 | 0.79 | ACLY (0.49) | CYP4F2CYP4A11PPARATTRCYP1A2 | |
| SCHEMBL5527551 | 0.78 | CYP4F2 (0.46) | CYP4F2CYP4A11TSHRTDP1ACLY | |
| SCHEMBL6256870 | 0.78 | CYP4F2 (0.42) | CYP4F2CYP4A11TSHRACLYACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1651205-A1 | METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISEASES WITH A STATIN AND ETHER | Warner-Lambert Company LLC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1572189-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1539127-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009431-A1 | METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISEASES WITH A STATIN AND ETHER | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CLEMSON UNIVERSITY | 2005-01-13 | — | — | US | disclosed |
| WO-2005002557-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ETHER AND SELECTIVE COX-2 INHIBITOR AND USES THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004045596-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| WO-2004017952-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | CYP4F2 1467/4885CYP4A11 3892/4885PPARA 273/4885 |
| US-20050009903-A1 | CB2-selective cannabinoid analogues | CNR2, CNR1, GPR68 | CYP4F2 3032/4885CYP4A11 508/4885PPARA 435/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | CYP4F2 3452/4885CYP4A11 1902/4885PPARA 33/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | CYP4F2 387/4885CYP4A11 56/4885PPARA 22/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | CYP4F2 137/4885CYP4A11 236/4885PPARA 224/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | CYP4F2 535/4885CYP4A11 325/4885PPARA 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.